Table of Contents

• Patient Profile & Clinical Background: A Colon Cancer Case Overview

• Why Patients Seek a U.S.-Based Second Opinion for Colon Cancer Treatment

• Disease Status & Diagnostic Findings in Advanced Colon Cancer

• Expert Review & Clinical Interpretation of Metastatic Colon Cancer

• Educational Consultation with a U.S. Specialist: Treatment Strategy Insights

• Patient Decided to go China For Treatment

• Why the Patient Chose Medical Travel to China for Colon Cancer Treatment

• Medebound HEALTH: A Trusted Partner for Medical Travel to China

• Connecting Patients with Leading Chinese Doctors for Colon Cancer Care

• Conclusion: Navigating Global Treatment Options for Colon Cancer Patients.

If you’re facing a diagnosis of advanced transverse colon adenocarcinoma, a U.S. second opinion can help you clarify treatment options and make informed decisions about cross-border care

This case study highlights how a patient from Malaysia sought clarity through an independent second opinion from leading U.S. specialists—and, with the support of Medebound HEALTH, successfully navigated a complex cross-border treatment journey to pursue advanced cancer care in China.

Medebound HEALTH played a pivotal role throughout the process, from curating and translating medical records, matching the patient with an appropriate U.S. oncology specialist, and coordinating a time-sensitive video consultation, to facilitating the transition to treatment in China with structured medical and logistical support.

As a U.S.-based cross-border medical coordination service founded in New York in 2015, Medebound HEALTH brings over a decade of experience in:

• Connecting international patients with top-tier medical resources in China

• Facilitating high-quality U.S. specialist second opinions

• Delivering end-to-end case management, from diagnosis review to treatment planning and overseas care coordination

By combining global medical expertise with localized execution, Medebound HEALTH ensures that patients receive accurate guidance, timely access to care, and a seamless treatment experience across borders.

Patient Profile & Clinical Background

The patient is a 64-year-old female diagnosed with stage IV transverse colon adenocarcinoma (pT4N2M1) with confirmed metastases to the liver, peritoneum, lymph nodes, and uterus.

Her disease course is characterized by aggressive local invasion and widespread systemic spread, including:

• Full-thickness tumor infiltration with positive circumferential margins

• Extensive lymphatic involvement (pericolic fat, omentum, mesenteric nodes)

• Peritoneal metastases and celiac axis lymph node involvement

• Secondary metastatic deposits in the liver and uterine structures

  
  

She also has a small intestine stoma following surgical intervention and a history of bilateral mastectomy for suspected DCIS.

Molecular profiling revealed:

• KRAS p.G12V mutation (Tier I)

• Additional mutations: PIK3CA, SMAD4, TP53, APC

• MSS (microsatellite stable)

• Low tumor mutational burden (TMB 3.4)

These findings are consistent with limited responsiveness to immunotherapy and currently no approved targeted therapies for her KRAS mutation outside clinical trials.

Why Colon Cancer Patients Seek the U.S.-Based Second Opinion?

The patient’s medical records were submitted for review by specialists affiliated with top-tier U.S. cancer institutions.

A second opinion at this level provides:

• Independent confirmation of diagnosis

• Evaluation of current treatment effectiveness

• Identification of alternative treatment strategies

• Insight into advanced therapies or clinical trials

• Evidence-based recommendations from global guidelines

  
  

It is important to note that the U.S. second opinion is based on medical record review only, without in-person physical examination. It does not establish a physician-patient relationship, provide emergency care, or issue medical prescriptions, and is intended to complement rather than replace local clinical care.

Disease Status & Diagnostic Findings

Post-surgical and imaging evaluations confirmed advanced metastatic disease:

• PET-CT (Dec 2025):

  • Liver metastasis (segment 4b)

  • Peritoneal metastasis

  • Celiac lymph node metastasis

  • Possible pulmonary lesions (under observation)

• Tumor markers:

  • Elevated CA 19-9, CA 72-4, CA 242, indicating active disease burden

  • Fluctuating marker levels suggest ongoing tumor activity

• Laboratory findings:

  • Generally preserved organ function

  • Intermittent hematologic fluctuations consistent with chemotherapy and supportive treatment effects

Expert Review & Clinical Interpretation

The second opinion highlighted an important medical principle:

This is a systemic metastatic disease, which means it cannot be controlled by localized treatments alone.

The cancer had already spread to areas such as the peritoneum and lymph nodes, indicating that a whole-body treatment approach was necessary. Local therapies alone would not be enough to manage all disease sites effectively.

At this stage, the primary goal of treatment is not cure, but to:

• Control disease progression

• Extend survival

• Maintain quality of life

Educational Consultation with the U.S. Specialist

Through Medebound HEALTH, the patient was provided with a high-priority educational video consultation with a leading U.S. oncology specialist. Given the urgency of the case, the patient’s family requested to arrange the consultation within one week.

Despite the complexity of the case and multi-party coordination involved, Medebound HEALTH successfully facilitated the consultation within the requested timeframe—ensuring no delay in critical decision-making.

Medebound HEALTH’s Role in Coordination

To make this possible, Medebound HEALTH provided comprehensive, end-to-end support:

• Medical Record Curation & Translation Organized, reviewed, and translated complex medical records into a structured clinical summary aligned with U.S. standards, enabling the specialist to quickly assess the case

• U.S. Specialist Matching Identified and connected the patient with a highly relevant U.S. oncology expert experienced in advanced colon cancer, ensuring the consultation was both targeted and high-value

• Multi-Party Coordination Under Time Constraints Managed scheduling across different time zones, coordinated with the physician’s team, and ensured all diagnostic materials were reviewed in advance

• Pre-Consultation Preparation & Post-Consultation Guidance Prepared the patient and family with key questions and expectations, and later helped interpret the specialist’s recommendations for practical next steps

Impact of the U.S. Specialist Consultation

This consultation played a critical role in:

• Explaining the disease and progression in clear, patient-friendly language

• Providing evidence-based treatment recommendations (including systemic therapy strategy) aligned with international guidelines

• Clarifying available options across countries, including the feasibility of continuing treatment outside the U.S.

• Building confidence and trust, enabling the patient and family to make informed decisions under pressure 

Recommended Treatment Approach

Based on expert evaluation, the recommended treatment was:

Systemic Chemotherapy (FOLFOX + Bevacizumab)

This is a globally accepted, evidence-based first-line treatment for advanced colorectal cancer.

It works by:

• Targeting cancer cells throughout the entire body

• Addressing both visible tumors and microscopic disease

• Providing better overall disease control compared to localized therapies

Patient Decided to go China For Treatment

After reviewing the key findings from the second opinion, the patient and their family felt more informed and confident about the next steps. With a clearer understanding of the diagnosis and available options, they carefully evaluated where they could access the most suitable care.

Given the need for advanced treatment, experienced specialists, and timely access to care, the patient ultimately decided to pursue treatment in China, where they could receive comprehensive and coordinated cancer management.

Why the Patient Chose Medical Travel to China for Colon Cancer Treatment

After carefully reviewing the U.S. second opinion, the patient and her family decided to pursue Medical Travel to China for continued colon cancer treatment. Their decision reflected a balance between clinical quality, treatment accessibility, and long-term affordability.

1. Advanced, Evidence-Based Care with Greater Clinical Depth than Regional Options

Compared to common regional destinations such as Malaysia, China offers:

• Highly developed multidisciplinary oncology (MDT) systems, ensuring coordinated decision-making across surgical, medical, and radiation oncology

• Extensive experience in managing complex and late-stage colorectal cancer, due to high patient volumes

• Broader integration of international treatment protocols (e.g., NCCN-aligned regimens) with real-world clinical expertise

This combination provided the patient with a higher level of confidence in managing advanced disease.

2. Seamless Integration of U.S. Second Opinion into Treatment Planning

• The Chinese MDT team directly implemented and optimized the FOLFOX + Bevacizumab regimen recommended by the U.S. specialist

• Treatment was personalized further based on the patient’s renal function, tolerance, and nutritional status

• Continuous evaluation ensured alignment with global best practices while adapting to the patient’s evolving condition

This level of integration ensured that the patient benefited from both U.S. expertise and China’s clinical execution.

3. Faster Access to Treatment Compared to the U.S. and Other Countries

• Minimal waiting time between consultation and treatment initiation

• Rapid coordination of imaging, diagnostics, and chemotherapy scheduling

• Immediate access to specialized oncology teams and advanced therapies

This was particularly critical given the progressive nature of metastatic colon cancer.

4. Cost-Effective Care Compared to the United States

• Significantly lower overall treatment costs than in the U.S., especially for long-term systemic therapy

• More sustainable financial model for ongoing care, including monitoring and supportive treatment

• Reduced out-of-pocket burden without compromising treatment quality

This allowed the patient to continue evidence-based therapy without financial interruption.

5. Access to Innovative and Emerging Cancer Therapies

China has rapidly advanced in oncology innovation, offering:

• Availability of cutting-edge treatments such as CAR-T cell therapy at major cancer centers

• Active participation in clinical trials and translational research

• Progress in natural killer (NK) cell–based immunotherapy, enhancing future treatment possibilities

6. Coordinated Medical Support: Enabling a Safer Transition to Higher-Quality Care

With professional medical coordination, the patient was able to move beyond the limitations of

regional care in Malaysia and access a more advanced, structured treatment system in China—while avoiding the high complexity and cost typically associated with treatment in the U.S.

Through this coordinated approach, the patient received:

• End-to-End Medical Record Management Complete organization, translation, and clinical structuring of medical records ensured that Chinese specialists could accurately interpret prior treatment history and seamlessly implement the U.S. second opinion. This level of precision is often less standardized in regional care transitions.

  
  

• Direct Access to High-Volume Oncology Specialists Coordination services connected the patient with experienced multidisciplinary teams in China who routinely manage advanced colon cancer cases, offering deeper clinical exposure compared to many centers in Malaysia.

  
  

• Efficient Treatment & Travel Planning Compared to the longer timelines and complex administrative processes in the U.S., the patient benefited from fast-track scheduling, visa support, and immediate treatment initiation—critical for progressive disease.

  
  

• Continuous Clinical and Logistical Guidance Ongoing support ensured real-time communication between the patient and care teams, helping manage side effects, adjust treatment, and maintain continuity—something that can be fragmented in cross-border care without coordination.

Ultimately, professional coordination transformed a complex international treatment journey into a well-managed, clinically optimized pathway, ensuring the patient received high-quality colon cancer care that was both accessible and financially sustainable.

Treatment Approach in China: Integrating U.S. Second Opinion into Clinical Practice

Building on the U.S. specialist’s recommendation of FOLFOX + Bevacizumab for advanced colon cancer, the multidisciplinary team (MDT) in China developed a personalized, evidence-based treatment plan. This approach ensured continuity of care while adapting the regimen to the patient’s clinical condition, including renal function and overall treatment tolerance.

Systemic Therapy

• Implementation of the recommended FOLFOX + Bevacizumab protocol as the first-line systemic treatment

• Dose modifications tailored to the patient’s renal function and tolerability

• Ongoing adjustments based on treatment response and adverse effects, following international clinical guidelines

Regular Monitoring

• Scheduled imaging assessments, including CT and PET-CT scans, to evaluate tumor response

• Serial tumor marker tracking (e.g., CEA levels) to monitor disease progression

• Continuous clinical evaluation by the MDT to refine the treatment strategy in real time

Supportive & Personalized Care

• Nutritional interventions designed to improve treatment tolerance and overall strength

• Proactive symptom management, including gastrointestinal and fatigue-related side effects

• Individualized side-effect control to maintain quality of life and treatment adherence

Integrated Care Outcome: The coordinated treatment plan successfully combined the global, evidence-based recommendations from the U.S. second opinion with China’s clinical expertise in advanced colorectal cancer. This cross-border approach allowed for both standardized therapy and personalized adjustments, optimizing treatment effectiveness while maintaining patient safety and quality of life.

The Value of a Second Opinion

This case highlights the importance of obtaining a second opinion, especially for complex or advanced cancer cases.

A second opinion can:

• Confirm or refine a diagnosis

• Identify better treatment options

• Prevent unnecessary or ineffective treatments

• Increase patient confidence

• Open access to global expertise

For many patients, it becomes a turning point in their treatment journey.

Medebound HEALTH: Your Partner for International Medical Travel to China

For patients looking for a dependable partner to support their medical travel to China, Medebound HEALTH has become a trusted name in international healthcare coordination. Established in New York in 2015, Medebound HEALTH brings over a decade of experience in cross-border teleconsultation and medical tourism in China, connecting patients from around the world with leading Chinese hospitals and specialists.

Note: Eligibility for our U.S. second opinion and cross-border medical coordination service is subject to clinical case complexity and specialist availability — not all cases may be eligible for review.

Strong Credentials and Leadership

Medebound HEALTH is a U.S.-based international medical organization guided by an experienced leadership team, including:

• Dr. Sheena Liu, founder with a PhD from Columbia University Medical School

• Former dean of New York Medical College, Dr. Connolly

• Mr. Castle, director at New York-Presbyterian Hospital

The company has earned recognition from Forbes for its innovative contributions to global healthcare. In addition, Medebound has built strong partnerships with major insurance providers such as Ping An, Taikang, and Pacific Life, enabling it to support a wide network of patients worldwide.

Connecting Patients with Leading Chinese Doctors

Through its extensive network, Medebound HEALTH provides direct access to top-tier medical resources across China. The company collaborates with highly regarded hospitals in cities such as Beijing, Shanghai, Hainan, and Guangzhou, including institutions affiliated with top universities like Tsinghua and Peking University, as well as leading hospitals in Shenzhen.

These partnerships allow patients to consult with some of the top 1% of medical experts in China, ensuring access to advanced treatment options and high-quality care as part of their medical travel to China journey.

Comprehensive Patient Support Services

Medebound HEALTH also offers a fully integrated support system to make the entire process smooth and stress-free. Their bilingual Chinese medical team composed of doctors from leading universities provides guidance at every stage, including:

• Pre-travel online consultations with Chinese specialists

• Personalized matching with the most suitable hospital and doctor

• Medical record translation and submission

• Visa application assistance

• Airport pickup and accommodation arrangements

• On-site interpretation during medical visits and treatments

• Post-treatment follow-up through teleconsultation and recovery monitoring

FAQ Section: Colon Cancer Second Opinion & Treatment in China

 What does a U.S. second opinion for colon cancer include?

A U.S. second opinion typically includes a detailed review of medical records by oncology specialists to evaluate diagnosis and treatment strategy.

The process involves:

① Reviewing pathology, imaging, and molecular reports

② Assessing cancer stage and spread

③ Evaluating current treatment effectiveness

④ Recommending evidence-based global treatment options

It is important to note that this is a medical record-based consultation, not an emergency service or physical examination.

In this case, the U.S. specialist confirmed that the disease was systemic and required whole-body treatment rather than localized therapy.

The second opinion helped clarify that the goal of treatment was disease control, survival extension, and quality of life improvement.

What treatment is usually recommended for stage IV metastatic colon cancer?

For stage IV metastatic colon cancer, systemic chemotherapy is the standard first-line treatment.

The most commonly recommended regimen includes:

• FOLFOX (chemotherapy combination)

• Bevacizumab (targeted therapy)

This approach works by:

• Treating cancer throughout the entire body

• Controlling both visible and microscopic disease

• Improving overall survival and disease stability

In this case, the U.S. specialist recommended FOLFOX + Bevacizumab as the primary evidence-based treatment strategy.

This global standard approach is widely used in advanced colorectal cancer care.

 Can colon cancer treatment be done in China after a U.S. second opinion?

Yes, patients can receive treatment in China based on a U.S. second opinion without losing continuity of care.

The treatment plan can be:

• Reviewed and validated by Chinese oncology MDT teams

• Adjusted based on patient condition and tolerance

• Implemented using globally accepted chemotherapy protocols

In this case, the Chinese multidisciplinary team directly adopted and optimized the U.S.-recommended FOLFOX + Bevacizumab regimen.

This integration ensures patients benefit from both international expertise and China’s clinical execution capabilities.

Why do patients choose China for colon cancer treatment?

Patients choose China for its combination of advanced oncology systems, faster treatment access, and cost-effective care.

Key advantages include:

• Highly experienced multidisciplinary oncology teams (MDT)

• Faster diagnosis and treatment initiation

• Access to modern cancer therapies and clinical trials

• Lower treatment costs compared to the U.S.

In this case, the patient selected China for continued treatment due to faster access, structured care systems, and long-term affordability.

China is increasingly recognized for its ability to manage complex metastatic cancers efficiently.

How does medical coordination support international cancer treatment?

Medical coordination ensures that patients can transition smoothly between countries, doctors, and treatment systems.

It typically includes:

① Medical record translation and structuring

② Matching with appropriate specialists

③ Scheduling consultations and treatment plans

④ Coordinating travel, visa, and hospital logistics

⑤ Providing follow-up and ongoing support

In this case, coordination played a critical role in linking the U.S. second opinion with treatment implementation in China.

Without structured coordination, cross-border care can become delayed and fragmented.

What is the benefit of getting both a U.S. second opinion and treatment in China?

Combining a U.S. second opinion with treatment in China provides both diagnostic clarity and practical access to care.

Benefits include:

• Independent confirmation of diagnosis

• Evidence-based global treatment recommendations

• Faster access to therapy in China

• Lower overall treatment cost

• Continuous care coordination

In this case, the patient used the U.S. second opinion to guide decision-making and then transitioned to China for efficient treatment execution.

This dual-system approach improves confidence and treatment efficiency.

Conclusion: Navigating Global Treatment Options for Colon Cancer Patients.

This case demonstrates how international second opinions can empower patients to make better-informed treatment decisions.

For patients in Malaysia and across Asia, China is becoming an increasingly important destination for cancer care, offering

• Advanced treatment options

• Experienced specialists

• Efficient and accessible care

• Innovative therapies

With the right guidance and support, patients can confidently explore global treatment options and take control of their healthcare journey.

Disclaimer:

We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician. All U.S. second opinions are provided by independent U.S.-licensed physicians in their individual professional capacity, and are not institutional services of any U.S. hospital or cancer center. Medebound HEALTH is an independent cross-border medical coordination service and is not affiliated with any hospital as an institution.